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Background: The appropriate thresholds for decisions on the cost-effectiveness of medical 
interventions remain controversial, especially in ‘end of life’ situations. Evidence of the 
values placed on different types of health gain by the general public is limited. 
Methods: Across nine European countries,  17,657 people were presented with different 
hypothetical health scenarios each involving a gain of one quality adjusted life year (QALY) 
and asked about their willingness to pay (WTP) for that gain. The questions included quality 
of life (QoL) enhancing and life extending health gains, and a scenario where respondents 
faced imminent, premature death.  
Results: Mean WTP values for a one-QALY gain comprised of QoL improvements were 
modest (PPP$11,000). When comparing QALY gains obtained in the near future the 
valuation of life extension exceeded the valuation of QoL enhancing gains (mean WTP 
PPP$19,000 for a scenario in which a coma is avoided). Mean WTP values were higher still 
when respondents faced imminent, premature death (PPP$29,000).  
Conclusions: Evidence from the largest survey on the value of health gains by the general 
public indicated a higher value for life extending gains compared to QoL enhancing gains. A 
further modest premium may be indicated for life extension when facing imminent, 










Implicit or explicit recognition of the need to ration care has contributed to the formation of 
institutions in a number of countries (e.g. National Institute of Health and Clinical Excellence 
(NICE) in the UK) whose duties include evaluating whether new health technologies should 
be provided by publicly funded health care systems. Underpinning these decisions is some 
measure of the benefit of the health technology evaluated; typically the Quality Adjusted 
Life Year (QALY), a measure which combines the impact of health changes on both health 
related quality of life (QoL) and life-years. Quantifying health gains in this manner allows 
decision making across a range of health programmes that maximises health gain (as 
assessed in QALYs) for a given health care budget. It also provides a measure to examine 
whether the distribution of health gains across society is equitable.(1) 
Decision making on the basis of a cost per QALY gained from a health technology requires 
stipulation of a threshold above which technologies are considered poor value for money. 
Methods to determine this threshold are contested. Conventional welfare economics would 
equate a health gain with the mean of individual willingness to pay (WTP) for the gain. Some 
researchers have advocated determining the general public’s WTP for a QALY as a means of 
setting an appropriate threshold.(2,3) Others have criticised WTP as an appropriate measure 
of the value of health gains, arguing instead that economists should seek to determine the 
shadow price of health gains given a health care budget determined through a political 
process.(4,5) Recently, it has been suggested that a combination of these two approaches is 
required.(6) Both approaches rest on an assumption that QALYs appropriately quantify 
health gains.  
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Studies have shown that QALYs gained in different circumstances are valued differently. 
Evidence suggests clinicians place a higher value on life extending QALYs compared to life 
enhancing QALYs.(7) Evidence based on modelling from existing general public studies  also 
suggests that values placed on a QALY may vary across QoL enhancing and life extending 
health gains.(8) The value of life extension close to death in HIV patients may approach four 
times the standard estimates of the monetary value of treatment effects.(9) It is unclear 
whether we can generalise values from a very specific clinical situation (such as the HIV 
patient above) to other scenarios. Debates about whether the value patients place on one 
QALY  is generic or varies dependent on context have therefore persisted for many 
years.(10)  Recently, NICE has indicated that a higher weight will be applied, in certain 
circumstances, to life-extending QALYs gained by patients who have a short life 
expectancy.(11) Policies initiated in Denmark, Belgium, Canada, Ireland and New Zealand 
(12-16) also suggest that politicians in many countries prioritise life extensions when facing 
premature death over other health gains. 
This paper reports selected results from the EuroVaQ study (European value of a QALY). 
EuroVaQ was funded by the European Commission to test different ways of deriving a monetary 
value of a QALY through surveys of the general public.(17) Two novel internet delivered surveys 
were developed and completed by 39,459 respondents across ten countries; Denmark, France, 
Hungary, Netherlands, Norway, Palestine, Poland, Spain, Sweden, UK. Two main elicitation 
approaches were used, the ‘direct’ and the ‘chained’ approach, of which only the former is relevant 
to this paper. Both approaches involved eliciting respondents maximum WTP for a health gain using 
an open-ended payment system. In the ‘chained’ approach respondents completed a standard 
gamble or time trade-off exercise to value a health state.(18) They were then presented with varying 
risks or durations of that health state such that the overall health gain was 0.05 or 0.1 QALYs. In 
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contrast, the ‘direct’ approach comprised scenarios offering health gains of predominantly 1 QALY.  
We report results from five questions from the direct questionnaire which were designed to 
allow comparison of WTP for different types of QALY (QALYs comprised of different Qol 
gains and life extensions). At the time of the study the Principal Investigator was based at 
Newcastle University in England and the project met the requirements of that University’s 





The ‘direct’ survey avoided reference to specific health states and aimed to minimise 
cognitively challenging valuations. Conducting the survey over the internet increased the 
potential sample size and allowed questions to be customized to individual respondent 
characteristics (such as age and life expectancy), whilst maintaining the same nominal 
health gain. Respondents were presented with health gains of predominantly one QALY. 
This contrasts with the more common approach where respondents are presented with a 
very small QALY gain, usually in a risk-based format, which requires multiplying up 
appropriately.  This direct approach was developed as a response to the methodological 
limitations of previous research which include limited discrimination between small risks, 
and unwillingness to state a valuation for certain but small health gains.(19) A full 





2.1 Health gains valued 
The five WTP questions which are the focus of this paper are highlighted in bold in Table I.  
Each presented a 1 QALY gain. With the exception of question C each question was 
presented as a health gain which would arise in a year’s time.  Two of the five questions (A 
and B) offered an improvement in QoL, a gain of 0.25 QALYs over four years (0.25*4) and a 
gain of 0.1 QALYs over ten years (0.1*10) respectively. The remaining three questions 
offered an extension of (conscious) life of one QALY. Question C (LEend) described an 
extension of one QALY at the end of respondents’ stated life expectancy; the other two 
offered an extension of conscious life, but in scenarios in which the gain occurred now 
rather than in the future. These latter two questions were specifically designed to aid 
comparison with questions offering a gain in QoL by ensuring the health gains commenced 
at the same point in time. Question E (terminal) placed respondents in a scenario of a 
terminal illness.  Question D (coma) presented respondents with a scenario in which they 
were facing a period in a coma on the assumption that time spent in a coma is equivalent to 
a shortening of life by that amount of time. The coma scenario was perhaps more contrived 
than the other questions. However, it was intended to elicit a value for a gain in longevity 
occurring in the near future and hence more comparable to the remaining questions than 
question C (LEend). The five questions, along with the remaing questions in the direct 
questionnaire, are summarised in Table 1A of the appendix. 
There is evidence in the literature of higher valuation on life extensions compared to  health 
gains arising from quality of life improvements.(7,8) However, the QALY gained in question C 
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(LEend) arises some time in the future, and we would expect values to be discounted on the 
assumption that individuals prefer health gains sooner than later.(20) Consequently, we 
hypothesised that questions D (coma) and E (terminal) would generate higher values than 
the remaining questions. We expected question E (terminal) to generate the highest values 
for two reasons. Firstly, we might expect respondents to place a higher value on an 
additional QALY when facing imminent death. Secondly, participants placed in a scenario of 
imminent death would be expected to display diminished marginal utility of income.  
2.2 Question framing 
First, respondents were introduced to the notion of measuring health on a visual analogue 
scale presented as a “health thermometer” ranging from death (zero) to full health (100).  
Generic health state descriptions were used to indicate different levels of health on the 
scale. These consisted of three EuroQoL EQ-5D-3L health states and approximate numerical 
valuations derived from UK survey values.(21)  Respondents were then asked to estimate 
their remaining life expectancy and rate their current health between 0 and 100 on the 
‘thermometer’. From their answers to these questions and their age, subsequent scenarios 
for WTP questions were presented graphically and tailored to each respondent’s own 
characteristics. The electronic questionnaire is accessible online at 
http://research.ncl.ac.uk/eurovaq/questionnaires.html.(22) 
A screen shot of question A (0.25*4) is displayed in Figure 1. In this example a 52 year old 
who expects to live to 80 years of age has rated her health at 90 points.  She is presented 
with the prospect of an illness which results in a loss of ‘health’ of 25 points (i.e. dropping to 
65 on the thermometer) commencing in one year and lasting for four years. (We assume 
that a 25 point loss in health, over four years and on a 0-100 scale where 0=death and 
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100=full health, amounts to a one QALY loss).  The respondent was then asked if she would 
pay anything to avoid the health loss. Payments were ‘out-of-pocket’, and respondents were 
encouraged to consider what they would be able to pay after thinking about their current 
income and savings and the possibility of a loan. If the respondent answered ‘yes’, a series 
of payment cards would appear at random on the screen and the respondent would be 
asked to sort them (via ‘clicking-and-dragging’ using the computer mouse) into amounts she 
definitely would pay, amounts she definitely would not pay and amounts about which she 
was unsure. The maximum card value the respondent definitely would pay and the 
minimum she definitely would not pay were then summarised, and the respondent asked to 
state her maximum WTP in an open ended response constrained by the summarised range. 
Nineteen cards ranging from £10 to £300,000 were converted into the respondents’ local 
currencies (with currencies converted at 2008 purchasing power parity rates). If the 
respondent declined to pay to avoid the health state she was asked to indicate reason(s) 
from a set of pre-coded responses or using a free text option. 
The remaining four questions reported here were presented in a similar manner. Question C 
(LEend) offered respondents the opportunity to buy an increase in life-years equivalent to 
one QALY. The duration and timing of the gain varied according to respondents’ reported 
health and age at which they expected to die. Hence a respondent reporting a health of 60 
and expecting to die at age 75 would be offered 20 months of additional life commencing at 
age 75. In question E (terminal) respondents were presented with the opportunity to delay 
imminent, premature death from a life threatening disease. The duration of the delay was 
adjusted according to the respondent’s own health so that the health gain amounted to one 
QALY. A screen shot of this question is displayed in Figure 2. Finally, question D (coma) 
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presented respondents with a scenario in which the individual would slip into a coma for an 
amount of time equal to one QALY, whereby the QALY would be lost imminently. 
Respondents were asked to assume that following the coma they would return to their 
current state of health and ‘pick up where you left off’.  
Respondents were excluded from question A (0.25*4) or B (0.1*10) if their resulting QoL 
would have fallen below 10 points. Respondents indicating that they expected to live less 
than six years were directed to another version of the questionnaire which included only 
questions offering health gains of short duration, and excluded question E (terminal). They 
are not reported here. Consequently, question E represented a scenario in which death 
would occur at least 6 years before respondents expected to die. 
2.3 Question ordering 
Table I illustrates the ordering of the relevant questions within each version of the 
questionnaire.  Version 1 contained question A (0.25*4) as the first question. In version 2 
questions C (LEend) and D (coma) were randomised to first or second, with question E 
(terminal) presented last. Version 3 contained question B (0.1*10) as the first question. 
Version 4 contained all five questions described above with questions A (0.25*4) and B 
(0.1*10) appearing first and second in random order. They were followed by questions C 
(LEend) and D (coma); also in random order. Question E (terminal) was the final question.  
2.4 Questionnaire Development and recruitment of subjects 
Question feasibility and validity were examined using focus groups in which pilot 
respondents (n>50 from four European countries) provided detailed feedback prior to 
development of the electronic survey. The pilots took place in computer suites with support 
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and observation from researchers and respondents’ comments were audio-recorded. 
Respondents were asked to comment on the credibility and clarity of the scenarios 
presented and their comments were used to refine and improve the presentation of 
questions. A prototype of the online survey was then tested in five countries and refined 
prior to launching the survey. 
We aimed to recruit a sample of 1500 respondents per country, and for these to be 
representative by age and gender, socio-economic status and region. Respondents were 
recruited from internet panels managed by Survey Sampling International (SSI; 
http://www.surveysampling.com/). In Palestine, where it was not possible to access an 
internet panel, a survey invitation was emailed to a list of contacts. The survey was launched 
on 23 November 2009 and closed on 28 February 2010.  Due to recruitment methods 
(inviting a large number of panel members to participate by email and closing when a 
sufficient number and types of respondents were achieved) standard response rates cannot 
be calculated. Drop-out rates for those commencing the survey were 32-48% across the 
nine European countries. These are higher than the typical rates for surveys from this 
company, which may reflect the complexity of the questions asked or the length of the 
questionnaire. Respondents were allocated to one of four questionnaire versions randomly 
until quotas for socio-demographic characteristics were achieved for each version in an 
attempt to achieve representativeness both within versions and across the entire sample. 
Respondents from demographic strata for which a sufficient number of responses had been 
collected across all surveys were screened out. Respondent characteristics are tabulated in 
the appendix (Table 2A).  With the exception of Palestine, the final sample was broadly 
representative but with significant under representation of elderly females and lower-
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income groups in some European countries. The 300 responses received from Palestine 
were clearly unrepresentative and consequently we excluded them. 
2.5 Data analysis 
The use of open ended questions allowed determination of mean and median values using 
the raw data avoiding the need to fit a regression model. We report mean and median WTP 
for a QALY derived from each question. As is conventional in WTP studies, we excluded 
‘protest respondents’ who were not willing to pay anything with the sole reason given that 
‘the government should pay’.(23) The other reasons for not being willing to pay were more 
difficult to classify as ‘protestors’ or ‘true zeros’. All responses other than ‘government 
should pay’ were interpreted as indicating a ‘true’ value of zero for the health gain in the 
base case analysis.  Respondents who indicated both a protest and other reason(s) for not 
wishing to pay were similarly assumed to value the health gain at zero.  
Means and medians are reported in $USPPP, in order to express monetary values elicited 
across countries in comparable currency. Country specific data and comparisons are 
available in the main report.(17) Confidence intervals around means within questionnaire 
versions were estimated using a two-stage bootstrapping procedure to allow for the 
hierarchical nature of the data across countries; we report bias corrected and accelerated 
confidence intervals.(24) We calculated 95% confidence intervals for the mean difference in 
WTP responses for selected question pairs using a two-stage bootstrapping routine; we also 
report p values for the paired t test for these question pairs. The latter test should be 
interpreted with caution given the extremely skewed distribution of the data. We undertook 
three sensitivity analyses. First, as undertaken previously in the value of life literature (25), 
in order to reduce the effect on means of extreme (arguably implausible) upper-end 
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responses, we ‘trimmed’ means and medians by excluding the top 1% WTP responses in 
each country. Second, we report means and medians after excluding all respondents who 
chose not to pay for health gains. Third, to investigate the impact of ordering effects we 
report means and medians after including only questions answered first in the 
questionnaire. 
We tested whether responses differed by questionnaire version using a Kruskal-Wallis test. 
We investigated whether differences arose due to differences in the likelihood of expressing 
a positive WTP or the magnitude of positive responses differed across questionnaire 
versions using, respectively, a Logit regression of WTP responses dichotomised as zero and 
non-zero (positive) values, and an ordinary least squares (OLS) regression of the log 
transformed positive WTP responses allowing for clustering at country level. This regression 
analysis was also used to investigate the impact of respondent characteristics (including 
income, education, social class, household size, age and sex) on the likelihood of a positive 
WTP response and the magnitude of positive responses. Details of this analysis are given in 
the appendix. 
All analysis was undertaken in Stata version 12. 
3. Results 
Around 8000 respondents answered each of the five questions (A to E) across the four 
questionnaire versions. Those electing not to pay for health gains ranged from 20% for 
question A (0.25*4) to 45% for question C (LEend) (Table II). A consistently small number (6-
8%) of respondents were labelled protestors. The reasons for refusing to pay are tabulated 
in the appendix (table 3A). Table III reports results by questionnaire version for questions A 
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to E. Clearly the WTP response data was highly skewed. Across the four versions mean 
values for a one QALY gain, (rounded) ranged from $8,000 to $31,000. In the responses to 
version 4 of the questionnaire confidence intervals around mean values for questions A 
(0.25*4), D (coma) and E (terminal) did not overlap indicating a significant difference. 
However, the same questions in questionnaire versions 1 and 2 generated confidence 
intervals that were not entirely distinct. The median values for question C (LEend) were 
particularly low, due to the very large number of zero responses for this question. For the 
remaining four questions, median values (rounded) ranged from $1,100 to $2,300.  
Table IV reports mean and median values after aggregation of responses for questions A to 
E across questionnaires. For completeness, aggregated values for the remaining questions (F 
to J) are reported in the appendix (Table 4A). The mean value for question D (coma) was 
approximately 75% higher than the mean for question A (25*4), and the mean value for 
question E (terminal) was about 50% higher than that for question D. The relative difference 
in medians across the three questions was smaller. Table IV also reports the sensitivity 
analyses. After trimming the top 1% of WTP-per-QALY values in each country, means were 
reduced by one third relative to the base case but proportional differences remained 
broadly the same. After excluding respondents who elected not to pay for the health gain, 
mean and median responses increased for all questions. The impact was greater for 
medians, especially for the longevity gains. The proportional difference in median values 
across questions A (25*4), D (coma) and E (terminal) for respondents electing to pay 
approached the magnitudes observed for mean values in the base case. The impact of 
including only questions answered first by respondents is modest for questions A (25*4), B 
(0.1*10) and C (LEend). Mean and median values for question D (coma) are higher. 
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Table V reports means and 95% confidence intervals of the difference in WTP responses 
across selected questions for respondents answering each respective pair of questions. The 
difference in means across questions A (25*4), D (coma) and E (terminal) were statistically 
significant. The paired t tests confirm the observations of significant differences between 
questions A, D and E. 
The results of the regression analyses of WTP values on respondent characteristics for each 
of the five questions are reported in the appendix (Tables 5A and 6A). Respondents in the 
Netherlands, UK and France were least likely to opt to pay for health gains, and respondents 
in Poland and Hungary were most likely. Respondents were more likely to pay if their 
education level, social class or income was higher, but the trend was weak for education and 
social class. A greater propensity to pay amongst older respondents was observed for 
questions A (0.25*4), B (0.1*10) and C (LEend), but not D (Coma) and E (Terminal). Men 
were less likely to elect to pay, as were healthier respondents. The coefficients on the terms 
for question order and version 4 indicated a lower propensity to pay for health gains in 
questions B, C and D when these question appeared later in the question sequence. 
After adjusting for respondent characteristics mean positive WTP values were highest for 
respondents from Spain, Denmark and Norway and lowest for respondents from the France, 
Hungary and Poland. Income, education and social class showed the expected relationship 
with WTP responses although the trend was weaker for social class. For questions A 
(0.25*4) and B (0.1*10) older age was associated with higher WTP. In contrast, questions D 
(coma) and E (terminal) showed the opposite trend with respect to age. Respondents 
reporting higher health reported higher WTP values for questions A (0.25*4), D (coma) and 
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E (terminal). The impact of gender was small, but men gave higher values. The impact of 
questionnaire version (reported as variable ‘version 4’) was not significant.  
Kruskal-Wallis tests confirmed the observation of differences in the distribution of 
responses to questions C (LEend) and D (coma) across versions 2 and 4 (p = 0.03 and p = 
0.01 respectively) but not question E (terminal) (p = 0.38). Kruskal-Wallis tests also 
confirmed a difference between versions 3 and 4 in responses to question B (0.1*10) (p = 
0.004), but not question A (0.25*4).  
4. Discussion 
From the results, a mean value ranging from $10,000 to $30,000 can be placed on one extra 
QALY estimated in scenarios involving certainty. Respondents differentiate between gains in 
life years in the near future and gains in QoL reflecting patterns suggested in earlier work 
(7,8). The advantage of our study is that values are elicited directly from large samples of 
the public as opposed to being indirectly modelled (8) or elicited from physicians.(7) 
Comparing these figures to the relevant stated-preference literature, the magnitude of 
responses reflect those of other studies in which values of QALY gains have likewise been 
elicited under conditions of certainty.(25-27) Studies in which respondents pay to avoid a 
small risk of a health loss typically generate higher values, such as that by Haninger and 
Hammitt which used risk of food poisoning in questions specifically designed to elicit a WTP 
per QALY and report values between $152,000 and $5,587,000 per QALY.(28) Similarly, 
studies which have used the Value of a Statistical Life as a basis for calculating the value of a 
QALY also generally result in higher WTP per QALY values than studies which have been 
specifically designed for this purpose.(18,29) 
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Mean values for QoL gains are invariant to the shape of the gain in terms of QoL and 
duration. The mean value for the life extending gain (LEend) is similar to the 0.25*4 gain. 
However, we would expect gains offered in the more distant future to be discounted which 
limits comparability with the QoL gains.(30) Assuming that time spent in a coma represents 
a shortening of life rather than a reduction in QoL, mean values indicate that QALYs 
comprised of gains in life years are valued around 75% higher than those comprised of gains 
in QoL. A further premium is evident for health gains in an end-of-life (terminal illness) 
scenario, the magnitude of which depends upon the comparator. Compared to gains in QoL, 
extension of life close to death is valued over 150% higher; compared to gains in longevity 
occurring at the same point in time (coma) the premium is 50%. Evidence that the public 
places a greater value on life extending QALYs compared to quality of life enhancing QALYs 
would suggest that the use of QALYs in cost-effectiveness analysis without additional 
weighting is inconsistent with welfare economics.(31) 
Inference from mean values is consistent with welfare theory.(32) Nevertheless, the data is 
highly skewed. Hence, it is reassuring to observe the same relative differences in mean 
values across the questions after excluding the top 1% of values. Evidence from median 
values that gains in longevity occurring now are valued higher than gains in QoL is weaker. 
However, median values are strongly influenced by large proportions of observations at zero 
as indicated by the very low value for question C (LEend). After excluding respondents who 
declined to pay (and were assigned a WTP of zero) the relative difference in median values 
across the five questions approaches the magnitude observed with the means. 
The size of the survey allowed us to identify differences in valuations of different types of 
health gain despite the highly skewed distribution of responses. We used a non-parametric, 
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two-stage bootstrapping routine to quantify sampling uncertainty in the data. This respects 
the hierarchical nature of the sampling frame and the distribution of the data. Achieving a 
large sample size required aggregation of data across countries, as well as age groups and 
other characteristics. It is likely that the relative differences in WTP values across questions 
vary by subgroup. Regression of log WTP values on patient characteristics demonstrates the 
expected relationship with household income, education and social class.  
By offering all respondents the same sized health gain our approach sidesteps the issue of 
whether to calculate an average of each respondent’s WTP per QALY or to calculate average 
values for WTP and health state valuations prior to deriving a WTP per QALY value (the so-
called mean-of-ratios or ratios-of-means problem).(33,34) It may be less cognitively 
demanding than the traditional approach to the Value of a Statistical Life where 
respondents are asked to value avoiding a small risk of a health loss.(35) The graphical 
displays were designed to further aid cognition. The electronic medium allowed us to 
present health gains in a personally relevant manner whilst maintaining the same nominal 
health gain across respondents. These aspects may have enhanced the validity of responses. 
However, the relatively large proportion of respondents electing not to pay for health gains 
might indicate that some respondents did not engage with the questionnaire. In this respect 
valuations obtained from an internet based survey may have less validity than a face-to-face 
questionnaire. Although active efforts were made to collect a representative sample we 
were constrained by the use of internet survey panels and struggled to recruit elderly 
women in some countries. It is possible that the exclusion of respondents who did not 
complete the questionnaire has introduced bias into estimated means and medians. 
However, it seems less likely that the differences we find in the magnitude of WTP per QALY 
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between questions are attributable to this. A further criticism that might be levelled at this 
approach is that valuations of large health gains are depressed by budget constraints.(36) 
Finally, we have assumed that the combination of ‘VAS type’ health ratings and duration, 
chosen to facilitate understanding of the questions, can be used to represent QALYs. This 
approach has been previously used in the derivation of QALY weights.(37) 
Evidence from across the four versions indicates a higher proportion of respondents electing 
not to pay when questions appeared later in the questionnaire, which might be attributable 
to respondent fatigue. This trend has been previously observed (38), and may explain the 
rather surprising observation that fewer respondents elected to pay for the health gain in 
question D (coma) when compared to questions A (0.25*4) and B (0.1*10), and fewer still 
elected to pay in question E (terminal). In this respect our estimate of the difference in 
values between questions A, D and E in the base case analysis is likely to be conservative. 
The relative differences are probably larger, as indicated by the sensitivity analysis which 
excluded questions not appearing first in the questionnaire version seen by each 
respondent. 
Reasons given by respondents for declining to pay for the health gain in the terminal illness 
scenario suggest that, despite the wording of the question, many of the respondents 
assumed the extra time would be spent in poor health. Although life extensions were 
described to respondents at their own current QoL as indicated on the thermometer, 
perceptions of QoL may well have been affected by the fact that people in our hypothetical 
question know they are going to die. Hence, all notions of hope are excluded. In the real 
world setting people still have a hope that they may live for a long time.(39) In this sense 
our form of question would inevitably lead to conservative valuations. 
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One interpretation of these results is that they are consistent with findings that the general 
public place a higher social value on health gains achieved from a lower or more severe 
health state.(,40,41) This need not surprise, since individually and socially focussed 
approaches do not necessarily differ in this regard, although aspects like solidarity and 
equity enter only in the latter.(42,43) Whilst we have interpreted question D (coma) as 
offering an extension of life, it may also be interpreted as a gain in QoL from a severe state 
(zero), and higher valuations may reflect this interpretation. One could further argue that 
question E (terminal) offers a health gain in a more severe scenario, although responses are 
more influenced in this scenario by the ‘dead anyway’ effect,(44) thus lowering many 
respondents’ perceptions of their marginal utility of income. Whilst such consistency is 
clearly possible the data are not entirely congruent with this argument. For example, there 
is no difference in mean values across questions A (0.25*4) and B (0.1*10) despite one 
offering a health gain from a lower initial health than the other. Of course, this could be 
because each of these is perceived as not being greatly different from each other in terms of 
severity. 
Clearly some caution is needed in interpreting the differences in values observed across the 
questions. Although respondents were reassured that they would be able to pick up their 
life as before on emerging from the coma, respondents may not have found this plausible 
and the resulting values may be inflated by concerns regarding the impact of the coma on 
relationships and employment.  
Caution is also needed when interpreting the premium on health gains when facing 
imminent death. Whilst the premium is large when compared to gains in QoL only, a 
contaminating factor in this comparison is the different types of health gain offered: QoL 
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gains in one scenario with life extension in the other. Question D (coma) was designed to 
overcome this, and the problem of life extension being interpreted by respondents as 
adding on time at the end of life. When comparing the mean for question D (coma) with 
that for question E (terminal), the ‘premium’ is reduced to 50%. 
One may also question the appropriateness of applying the valuations expressed in question 
E (terminal) as a guide for allocating public (or private) insurance resources. A core concept 
in economics is that all investments are associated with opportunity costs since investment 
of resources in a given project will initiate reduced possibilities (and thus loss of utility) 
elsewhere.(45) For the person who is facing death this rule may not apply, since money may 
be more or less worthless to the individual and the notion of opportunity costs nonsensical, 
although this is tempered somewhat by a desire to leave a legacy. Hence, it is natural for the 
person facing the prospect of imminent death to express high valuations (in terms of WTP) 
for life extensions, both because such life extensions are highly valued (either because doing 
something initiates hope, or because one values the extra time spent with family and 
friends) and because opportunity costs are low or nonexistent. It is therefore perfectly 
understandable and may indeed be utility maximising behaviour for such individuals to 
spend large sums of money out-of-pocket on interventions, which in reality offer only a 
chance of a minor life extension. However, if the health care intervention is financed by a 
common pool of funds (be this public or private) it is the general public (who are not facing 
death in the near future) who are to finance the health care intervention, and for whom the 
opportunity cost of spending additional dollars on terminal illness programmes may well be 





Results from the largest ever survey of the general public support previous findings of 
modest valuations of health gains elicited under certainty. This paper has demonstrated 
some of the complexities associated with trying to elicit values for different types of one-
QALY gain, especially for different forms of life-extending QALYs: eliciting preferences for 
health amongst patients who are facing death is not straightforward, as it conflates issues of 
QoL versus length of life as well as whether such gains happen in a terminal illness as 
opposed to another scenario.  
Findings in this study support previous evidence that life extending health gains are valued 
more highly than QoL gains. Evidence for a premium on end-of-life (terminal illness) QALYs 
depends on how the results are interpreted. On one hand, compared with typical contexts 
for gaining QALYs, such a premium would appear to exist and to reflect judgments of major 
health technology assessment bodies. On the other hand, relative to another life extending 
scenario designed specifically to aid comparison with terminal illness, the premium is much 
smaller. Given the likelihood that utility of income falls in a terminal illness scenario, this 
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Table I. Questionnaire layout 
 
Version 1 Version 2 Version 3 Version 4 
Question A 
(0.25*4) 
25 point loss over 
4 years now 
Question 
C (LEend 
 extra life 






Question B (0.1*10) 
 
10 point loss over 













25 point loss over 
4 years near end 
of life 
Question G 
10 point loss over 


























10% risk of 10 















25 point loss over 
4 years now with 
payment over 4 
years 
Question E (terminal 
illness) 
extra life now 
Question E (terminal 
illness) 
extra life now 
Questions shown in adjacent boxes separated by a dashed line were presented in random order to 
participants.   
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Qu. A (25*4) 8511 1716 (20.2%) 541 (6.4%) 
Qu. B (0.1*10) 8374 1899 (22.7%) 545 (6.5%) 
Qu. C (LEend) 8955 4027 (45.0%) 656 (7.3%) 
Qu. D (Coma) 8933 2588 (29.0%) 751 (8.4%) 
Qu. E (terminal)  8745 2931 (33.5%) 655 (7.5%) 
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Questionnaire version 4 
Qu. A (25*4) 3,957 614 (15.5%) 10,724 (8,995 – 13,178) 1,532 133,417 2,156,605 
Qu. B (0.1*10) 3,803 751 (19.7%) 11,497 (9,252 – 17,455) 1,078 127,646 5,391,513 
Qu. C (LEend) 3,935 1729 (43.9%) 8,309 (6,947 – 10,363) 149 125,203 1,531,755 
Qu. D (Coma) 3,889 973 (25.0%) 18,675 (15,583 – 22,456) 1,791 453,617 3,063,510 
Qu. E (terminal) 3,949 1137 (28.8%) 30,563 (25,893 – 37,268) 2,293 515,969 4,636,701 
Questionnaire version 2 
Qu. C (LEend) 4,147 1704 (41.1%) 12,986 (9,537 – 20,027) 191 229,978 6,670,838 
Qu. D (Coma) 4,101 893 (21.8%) 19,385 (16,096 – 25,194) 2,149 284,551 5,318,588 
Qu. E (terminal) 4,118 1186 (28.8%) 27,622 (23,252 – 35,569) 2,096 459,957 7,717,024 
Questionnaire version 1 
Qu. A (25*4) 3,981 610 (15.3%) 10,763 (8,458 – 15,788) 1,334 126,488 4,669,587 
Questionnaire version 3 
Qu. B (0.1*10) 4,002 656 (16.4%) 11,357 (9,720 – 13,619) 1,150 199,186 1,149,892 




Table IV. Value of one QALY aggregated across questionnaire versions with and without trimming at 1% and after excluding respondents 






WTP values aggregated 
across questionnaire 
versions (base case) 
Top 1% of positive values 
excluded (by country) 
WTP values for respondents 
agreeing to pay 
WTP values derived from 




WTP ($USPPP)  
n 
WTP ($USPPP)  
n 
WTP ($USPPP)  
n 
WTP ($USPPP) 
Mean Median Mean Median Mean Median Mean Median 
Qu. A (25*4) 7,938 10,744 1,450 7,867 6,992 1,433 6,763 12,610 2,163 5,974 10,165 1,379 
Qu. B (0.1*10) 7,805 11,425 1,138 7,737 7,093 1,098 6,451 13,823 2,070 5,904 12,576 1,150 
Qu. C (LEend) 8,082 10,709 160 8,031 6,077 155 4,701 18,411 1,791 2,053 8,683 155 
Qu. D (Coma) 7,990 19,039 2,096 7,925 13,618 1,941 6,162 24,687 3,829 2,075 25,013 2,875 
Qu. E (terminal)  8,067 29,062 2,196 8,005 20,928 2,149 5,792 40,477 5,392 - - - 
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Table V. Mean ‘within-respondent’ differences in values between questions (respondents 
answering more than one question)  
 






paired t test 
Questionnaire version 4   
Qu. A (0.1*10) – Qu. B (0.25*4) 3,700 565 -1,183 to 4,209 0.6 
Qu. C (LEend) – Qu. A (0.25*4) 3,797 -2,468 -4,412 to -737 0.008 








Questionnaire version 2   







Figure 1 Screen shot of question A (0.25*4) 
















Table 1A. Summary of questions forming the EuroVaQ direct questionnaire. 
QALY 
gain 
Question Timing Health 
loss/gain 
Duration Risk 
1 A 1 year’s time 25 point loss 4 years certainty 
1 B 1 year’s time 10 point loss 10 years certainty 
1 C Near end of life year of life varies certainty 
1 D 1 year’s time year of life varies certainty 
1 E 1 year’s time year of life varies certainty 
1 F Near end of life 25 point loss 4 years certainty 
1 G Near end of life 10 point loss 10 years certainty 
1 H* 1 year’s time 25 point loss 4 years certainty 
0.25 I 1 year’s time 25 point loss 1 year certainty 
0.1 J 1 year’s time 10 point loss 1 year certainty 
0.1 K 1 year’s time 25 point loss 4 years 10% risk 
0.1 L 1 year’s time 10 point loss 10 years 10% risk 
0.05 M 1 year’s time 25 point loss 4 years 5% risk 
*In question H respondents were asked to pay for the health gain in yearly instalments 
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Table 2A. Respondent characteristics by country  
 
 Netherlands UK France Spain Sweden Norway Denmark Poland Hungary Palestine 
Number of respondents 2148 1778 2088 2167 1872 1634 2234 1812 1924 300 
Proportion male 49.3% 47.7% 46.7% 51.7% 44.7% 52.8% 49.5% 51.7% 50.5% 71.7% 



















Mean stated life 



















Mean stated health - VAS 



















Mean household size (sd) 2.4 (1.3) 2.5 (1.4) 2.6 (1.5) 2.8 (1.3) 2.3 (1.3) 2.5 (1.3) 2.2 (1.2) 3.2 (1.4) 2.8 (1.3) 7.5 (6.7) 
Head of household* 72.7% 71.0% 66.4% 61.8% 76.8% 77.8% 76.1% 62.5% 66.8% 57.7% 
Degree** 34.8% 27.8% 40.6% 36.8% 43.4% 51.5% 45.7% 53.7% 17.6% 48.3% 
Respondent employed 52.1% 50.3% 50.7% 53.1% 50.3% 61.3% 50.0% 64.0% 62.0% 49.3% 
Household income 72,733 95,588 47,436 62,517 59,630 106,011 112,276 38,018 19,116 3,731 
Missing income 19.2% 12.0% 9.0% 15.3% 9.3% 10.3% 10.0% 14.8% 11.4% 11.0% 
*Proportion of respondents who state they are the head, or the joint head of the household. **Proportion of respondents educated to degree level.  
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Qu. A (25*4) 21% 16% 34% 45% - - - - 8% 
Qu. B (0.1*10) 32% 17% 29% 43% - - - - 8% 
Qu. C (LEend) - - 20% 30% 30% 35% 23% - 10% 
Qu. D (Coma) 23% 22% 29% 43% - - - - 9% 
Qu. E (terminal)  - - 21% 36% - - 48% 19% 7% 
Table Key 
Could live with it It wouldn't be too bad/I could live with it. 
Get better anyway I would get better anyway, so it is not worth paying for the treatment. 
Can't afford it I do value the treatment, but I cannot afford to pay anything for it. 
Govt should pay I do value the treatment, but do not want to pay because the government should provide 
health care. 
Gain is too small It’s not enough of a gain to be of value to me. 
May be dead then I may not live until that age, so it is not worth paying for treatment now. 
Health poor during gain I may be in poor health at that age, so it is not worth paying for treatment (life extension)/If 
I was going to die this would only be paying to prolong my death (terminal illness) 
Wish to leave legacy I am thinking about my family/partner – I would want to leave the money to them. 
* Respondents not restricted to one answer, hence row totals exceed 100% 
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 Table 4A: mean and median WTP per QALY for questions not reported in the main text 
 




Gain in QoL of 1 QALY over 4 
years near end of life 3,886 10,685 334 
Gain in QoL of 1 QALY over 10 
years near end of life 4,041 46,686 4,313 
Gain in QoL of 0.25 QALYs over 
1 year now 4,074 104,733 3,723 
Gain in QoL of 0.1 QALYs over 1 
year now 3,800 11,795 517 
10% risk of loss in QOL of 1 
QALY over 4 years now 4,043 119,975 3,582 
5% risk of loss in QOL of 1 QALY 
over 4 years now 4,038 177,996 3,293 
10% risk of loss in QOL of 1 
QALY over 10 years now 3,750 81,740 5,319 
Gain in QoL of 1 QALY over 4 
years now with yearly payment 3,857 34,479 3,064 
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Regression of WTP responses on patient characteristics 
The distribution of WTP response data was both highly skewed and included significant zero values. 
Consequently, regression analysis for each question was undertaken in two parts. The proportion of 
zero valuations was modelled as a function of respondent characteristics and questionnaire version 
using Logit regression. The distribution of positive response data was approximately normal after log 
transformation. Hence, positive WTP values were modelled using OLS regression after conversion to 
USD and log transformation. We found no evidence of heteroskedasticity in the log transformed 
data (p = 0.9). However, we chose to cluster on country, thus ensuring that we estimated robust 
standard errors. 
We pre-specified the inclusion of the following covariates: age, sex, income, education, social class, 
household size, initial health (as reported by respondent’s on the ‘thermometer’) and included 
dummy variables indicating questionnaire version and question ordering. Within each country 
respondents were assigned to quintiles on household income with a sixth category for respondents 
who failed/refused to state their income. Respondents were assigned to three levels of education 
based on whether they had completed compulsory education only; some further education; or had 
completed a degree or equivalent. Household size was analysed as the OECD coefficient which sums 
a score of one for the first household member; 0.5 for additional members aged over 13; and 0.3 for 
children under 14. Social class was assigned using ESOMAR categories which are based on job 
description and age on leaving education (European Society for Opinion and Marketing Research. 
Standard demographic segmentation. A system of international socio-economic classification of 
respondents to survey research 1997. Available at www.esomar.org) 
An area of potential concern was the risk of endogeneity for the variable reporting respondents’ 
health. Respondents’ reported health influenced the presentation of each health gain to that 
respondent via the customisation of the questions. We tested for this with a Durbin-Wu-Hausman 
test and found no evidence of endogeneity (p = 0.2). The results of the Logit and OLS regressions for 




Table 5A. Coefficients from Logit regression of WTP responses against respondent characteristics 
  
Coefficient 




Country Netherlands -0.757*** -0.71*** -0.942*** -0.814*** -0.758*** 
 UK -1.014*** -0.893*** -0.665*** -0.813*** -0.698*** 
 France -0.464*** -0.383*** -0.516*** -0.752*** -0.849*** 
 Spain -0.497*** -0.199*** -0.132*** -0.209*** -0.583*** 
 Sweden -0.099*** -0.099*** -0.132*** -0.226*** -0.076*** 
 Denmark -0.068*** -0.046* -0.523*** -0.422*** -0.323*** 
 Poland 0.176*** 0.707*** 0.202*** -0.262*** -0.17*** 
 Hungary 0.029 0.129** 0.041 -0.176*** -0.319*** 
Age range Age 18 to 25 -0.321* -0.428** -0.564*** 0.239** 0.065 
 Age 26 to 35 -0.369*** -0.387*** -0.44*** 0.087 0.035 
 Age 36 to 45 -0.258*** -0.261** -0.211* 0.116 0.004 
 Age 56 to 65 0.01 0.057 0.337*** 0.038 0.03 
 Age over 65 0.169 0.299* 0.497*** 0.13 0.053 
Income Income missing -0.577*** -0.595*** -0.294 -0.419** -0.322* 
 Income lowest -0.601*** -0.633*** -0.291*** -0.484*** -0.317*** 
 Income low -0.318** -0.423*** -0.169 -0.149 -0.158 
 Income higher 0.287* 0.004 -0.018 0.178* 0.14 
 Income highest 0.197 0.227 0.206 0.326** 0.242 
Education Low education -0.27* -0.221** -0.08 -0.104 -0.235** 
 High education 0.135 0.094 -0.035 0.027 0.229** 
Social class Social Group A 0.233 0.313*** 0.15* 0.302** 0.16* 
 Social Group B 0.426*** 0.234 0.058 0.121 -0.067 
 Social Group C1 0.142 0.166 0.044 0.208* 0.077 
 Social Group D 0.093 0.155 -0.031 0.08 -0.003 
 Social Group E -0.056 -0.059 -0.139 -0.028 -0.178 
Other Male -0.133 -0.175* 0.088 -0.268** -0.285*** 
 Household size -0.046 -0.105 0.034 0.028 0.009 
 Health (VAS) 0.004 -0.004*** -0.004*** 0.011*** 0.008*** 
 Question order -0.011 0.323*** 0.093* -0.308*** - 
 Version 4 -0.019 -0.229*** -0.14*** -0.212*** -0.011 
 Constant 2.135*** 2.603*** 1.111*** 1.010*** 0.799*** 
 Adjusted R
2
 0.057 0.064 0.048 0.049 0.041 
*Coefficient with p value < 0.05, **Coefficient with p value < 0.01, ***Coefficient with p value < 0.001 
Base country is Norway; base income and education category is middle; base social group is C2 
For the QoL gain questions the Question order variable indicates that the 0.1*10 question appeared before the 0.25*4 
question; for the Coma and life extension questions the Question order variable indicates that the life extension question 




Table 6B. Coefficients from regression of log WTP responses against respondent characteristics 
  
Coefficient 




Country Netherlands -0.395*** -0.117*** -0.248*** -0.441*** -0.491*** 
 UK -0.343*** -0.229*** 0.069* -0.263*** -0.017 
 France -1.018*** -0.836*** -0.734*** -1.141*** -1.083*** 
 Spain -0.302*** -0.03 0.174*** 0.075** 0.002 
 Sweden -0.418*** -0.405*** -0.255*** -0.399*** -0.503*** 
 Denmark 0.13*** 0.336*** 0.13*** 0.158*** 0.147*** 
 Poland -0.847*** -0.798*** -0.657*** -1.159*** -1.093*** 
 Hungary -0.899*** -0.798*** -0.836*** -1.15*** -1.065*** 
Age range Age 18 to 25 0.088 0.028 0.103 0.386** 0.779*** 
 Age 26 to 35 0.033 -0.111* -0.088 0.224*** 0.38** 
 Age 36 to 45 0.018 -0.127 -0.115 0.124 0.231** 
 Age 56 to 65 0.174* 0.186** -0.002 -0.052 -0.227** 
 Age over 65 0.297** 0.32* 0.132 -0.073 -0.371* 
Income Income missing -0.115 -0.022 -0.022 -0.122 -0.114 
 Income lowest -0.502** -0.372** -0.511** -0.504*** -0.521*** 
 Income low -0.251* -0.234* -0.298* -0.194** -0.251** 
 Income higher 0.201* 0.238** 0.16 0.172* 0.196 
 Income highest 0.478** 0.587** 0.44** 0.572*** 0.594*** 
Education Low education -0.253** -0.343*** -0.189 -0.292* -0.311** 
 High education 0.18** 0.203** 0.171* 0.313*** 0.368*** 
Social class Social Group A 0.377** 0.266** 0.396** 0.278* 0.405** 
 Social Group B 0.282** 0.261** 0.112 0.144 0.285** 
 Social Group C1 0.098 0.07 0.017 0.014 0.169 
 Social Group D 0.015 -0.002 0.08 -0.088 0.083 
 Social Group E -0.095 -0.14 -0.209 -0.255** -0.16 
Other Male 0.218** 0.142* 0.182* 0.093 0.132* 
 Household size -0.126* -0.122** -0.189* -0.159* -0.181** 
 Health (VAS) 0.006** 0.001 0.002 0.007** 0.009** 
 Question order 0.072 -0.014 -0.436** -0.281** - 
 
 Version 4 0.08 -0.007 -0.007 0.018 0.076 
 Constant 7.385*** 7.697*** 8.009*** 8.250*** 8.132*** 
  R
2
 0.123 0.118 0.109 0.150 0.157 
*Coefficient with p value < 0.05, **Coefficient with p value < 0.01, ***Coefficient with p value < 0.001 
Base country is Norway; base income and education category is middle; base social group is C2 
For the QoL gain questions the Question order variable indicates that the 0.1*10 question appeared before the 0.25*4 
question; for the Coma and life extension questions the Question order variable indicates that the life extension question 
appeared before the coma question 
 
